journal
MENU ▼
Read by QxMD icon Read
search

Global Cardiology Science & Practice

journal
https://read.qxmd.com/read/30393649/foreword-to-the-special-issue-hcm-in-2018
#1
EDITORIAL
Perry Elliott
No abstract text is available yet for this article.
August 12, 2018: Global Cardiology Science & Practice
https://read.qxmd.com/read/30393648/the-genetics-of-hypertrophic-cardiomyopathy
#2
REVIEW
Mohammed Akhtar, Perry Elliott
Hypertrophic cardiomyopathy (HCM) is most commonly transmitted as an autosomal dominant trait, caused by mutations in genes encoding cardiac sarcomere proteins1-3 . Other inheritable causes of the disease include mutations in genes coding for proteins important in calcium handling or that form part of the cytoskeleton4-6 . At present, the primary clinical role of genetic testing in HCM is to facilitate familial screening to allow the identification of individuals at risk of developing the disease7,8 . It is also used to diagnose genocopies, such as lysosomal9-11 and glycogen storage disease which have different treatment strategies, rates of disease progression and prognosis12-14 ...
August 12, 2018: Global Cardiology Science & Practice
https://read.qxmd.com/read/30393647/surgical-myectomy-rationale-and-personalized-technique
#3
EDITORIAL
Hamood N Al Kindi, Magdi H Yacoub
Septal myectomy is currently the gold standard treatment for symptomatic patients with hypertrophic cardiomyopathy. The procedure needs to be tailored and performed in a personalized fashion, taking into consideration the anatomical spectrum of this disease. The procedure needs to address the various components that contribute to the clinical and pathological picture of this disease including, the fibrous trigones, accessory tissues, papillary muscles, mitral valve and myocardial bridges. The operation can be performed with very low mortality and morbidity in high-volume experienced centers with predictable excellent short and long-term outcomes...
August 12, 2018: Global Cardiology Science & Practice
https://read.qxmd.com/read/30393646/introduction-to-the-special-issue
#4
EDITORIAL
Magdi Yacoub, Robert O Bonow
No abstract text is available yet for this article.
August 12, 2018: Global Cardiology Science & Practice
https://read.qxmd.com/read/30393645/follow-up-and-prognosis-of-hcm
#5
REVIEW
Fernando Dominguez, Jorge Sanz-Sánchez, Pablo García-Pavía, Esther Zorio
No abstract text is available yet for this article.
August 12, 2018: Global Cardiology Science & Practice
https://read.qxmd.com/read/30393644/heart-transplantation-in-patients-with-hypertrophic-cardiomyopathy
#6
REVIEW
Marta Farrero Torres, Felix Perez-Villa
No abstract text is available yet for this article.
August 12, 2018: Global Cardiology Science & Practice
https://read.qxmd.com/read/30393643/implantable-cardioverter-defibrillator-in-hypertrophic-cardiomyopathy
#7
REVIEW
Diego Jimenez Sanchez, Ignacio Fernández Lozano
Sudden cardiac death (SCD) is the most devastating complication in hypertrophic cardiomyopathy (HCM). The implantable cardioverter-defibrillator (ICD) has proven to be effective in SCD prevention in several clinical scenarios. In HCM population, it has demonstrated to successfully abort life-threatening ventricular arrhythmias despite the extreme morphology characteristic of HCM, often with massive degrees of left ventricular hypertrophy and/or LV outflow tract obstruction. Studies showed a high rate of appropriate intervention in secondary prevention and in primary prevention of patients considered at high risk...
August 12, 2018: Global Cardiology Science & Practice
https://read.qxmd.com/read/30393642/alcohol-septal-ablation-in-hypertrophic-cardiomyopathy
#8
REVIEW
Juan José Santos Mateo, Juan R Gimeno
Alcohol septal ablation (ASA) has become an alternative to surgical myectomy in obstructive hypertrophic cardiomyopathy since it was first introduced in 1994 by Sigwart. The procedure alleviates symptoms by producing a limited infarction of the upper interventricular septum, resulting in a decrease in left ventricular outflow tract (LVOT) gradient. The technique has been improved over time and the results are comparable with those of myectomy. Initial concerns about long-term outcomes have been largely resolved...
August 12, 2018: Global Cardiology Science & Practice
https://read.qxmd.com/read/30393641/cardiac-pacing-in-patients-with-hypertrophic-obstructive-cardiomyopathy
#9
REVIEW
José Maria Tolosana, Emilce Trucco
No abstract text is available yet for this article.
August 12, 2018: Global Cardiology Science & Practice
https://read.qxmd.com/read/30393640/storage-diseases-with-hypertrophic-cardiomyopathy-phenotype
#10
REVIEW
Luis Ruiz-Guerrero, Roberto Barriales-Villa
Never judge a book by its cover, nor assume hypertrophic cardiomyopathy (HCM) as sarcomeric, as appearances can deceive. HCM phenocopies account for a 5-10% of the cases, mainly represented by storage diseases, flagged by the increasing prevalence of senile cardiac amyloid in developing countries. Multisystemic and heterogeneous presentation of these entities is a challenge for clinicians, and time delay in diagnosis is a major concern. Promising drugs and gene-specific tailored therapies are under development, therefore, more than ever, appropriate understanding of these conditions is mandatory for adequate early treatment and counselling...
August 12, 2018: Global Cardiology Science & Practice
https://read.qxmd.com/read/30393639/neuromuscular-diseases-with-hypertrophic-cardiomyopathy
#11
REVIEW
Sergi Cesar
No abstract text is available yet for this article.
August 12, 2018: Global Cardiology Science & Practice
https://read.qxmd.com/read/30393638/hypertrophic-cardiomyopathy-with-little-hypertrophy-and-severe-arrhythmia
#12
REVIEW
Tomas Ripoll-Vera, Jorge Alvarez-Rubio
No abstract text is available yet for this article.
August 12, 2018: Global Cardiology Science & Practice
https://read.qxmd.com/read/30393637/hypertrophic-cardiomyopathy-sudden-cardiac-death-risk-stratification-in-adults
#13
REVIEW
Paloma Jordà, Ana García-Álvarez
No abstract text is available yet for this article.
August 12, 2018: Global Cardiology Science & Practice
https://read.qxmd.com/read/30393636/risk-stratification-in-childhood-hypertrophic-cardiomyopathy
#14
REVIEW
Gabrielle Norrish, Juan Pablo Kaski
No abstract text is available yet for this article.
August 12, 2018: Global Cardiology Science & Practice
https://read.qxmd.com/read/30393635/perspectives-on-current-recommendations-for-genetic-testing-in-hcm
#15
REVIEW
Lorenzo Monserrat
No abstract text is available yet for this article.
August 12, 2018: Global Cardiology Science & Practice
https://read.qxmd.com/read/30393634/cardiac-magnetic-resonance-imaging-in-the-evaluation-of-patients-with-hypertrophic-cardiomyopathy
#16
REVIEW
Juan Carlos Brenes, Adelina Doltra, Susanna Prat
No abstract text is available yet for this article.
August 12, 2018: Global Cardiology Science & Practice
https://read.qxmd.com/read/30393633/added-value-of-cardiac-deformation-imaging-in-differential-diagnosis-of-left-ventricular-hypertrophy
#17
REVIEW
Filip Loncaric, Bart Bijnens, Marta Sitges
No abstract text is available yet for this article.
August 12, 2018: Global Cardiology Science & Practice
https://read.qxmd.com/read/30393632/histopathology-in-hcm
#18
REVIEW
Beatriz San Millán Tejado, Cristina Jou
No abstract text is available yet for this article.
August 12, 2018: Global Cardiology Science & Practice
https://read.qxmd.com/read/30393631/clinical-presentations-of-hypertrophic-cardiomyopathy-and-implications-for-therapy
#19
REVIEW
Carles Díez-López, Joel Salazar-Mendiguchía
No abstract text is available yet for this article.
August 12, 2018: Global Cardiology Science & Practice
https://read.qxmd.com/read/30083548/cardiac-amyloidosis-the-great-masquerader
#20
Jubran Rind, Nagib Chalfoun, Richard McNamara
Cardiac amyloidosis is an elusive condition that is notorious for mimicking various cardiovascular conditions that present with left ventricular hypertrophy (LVH). The hypertrophy in amyloidosis is typically diffuse; however, rare reports of echocardiographic resemblances with hypertrophic cardiomyopathy (HCM) exist, such as asymmetric septal hypertrophy and left ventricular outflow tract obstruction. Cardiac MRI can help differentiate amyloidosis from hypertrophic cardiomyopathy in unclear situations. This differentiation from HCM and other forms of cardiomyopathy has important treatment implications...
June 30, 2018: Global Cardiology Science & Practice
journal
journal
48227
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"